Norspan (Buprenorphine)

Buprenorphine binds with high affinity to the μ‑opioid receptor as a partial agonist, activating the receptor enough to produce analgesia while limiting the ceiling effect on respiratory depression. It also blocks κ‑opioid receptors, which can reduce dysphoric effects and contribute to its overall pain‑modulating profile.

The prescribed dose of Norspan is determined by the treating physician based on the patient’s pain severity, opioid tolerance, and clinical response. Available patch strengths release 5, 10, 15, or 20 µg of buprenorphine per hour, and the clinician selects the appropriate strength and duration of therapy.

Safety data for buprenorphine transdermal patches in pregnancy and lactation are limited. The drug crosses the placenta and may be present in breast milk, so the potential risks to the fetus or infant must be weighed against the benefits of pain control. Clinicians should use it only if clearly needed and after consulting obstetric guidelines.

To order Norspan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Norspan (buprenorphine) differs from fentanyl patches in that buprenorphine is a partial μ‑opioid agonist with a ceiling effect on respiratory depression, potentially offering a safer profile for certain patients. Fentanyl is a full agonist and may provide stronger analgesia but carries a higher risk of respiratory compromise. Choice depends on individual patient factors and clinician judgment.

Norspan patches should be stored at room temperature, preferably below 30 °C, in their original packaging to protect from light and moisture. Keep the patches out of reach of children and do not expose them to extreme heat or direct sunlight, as this may affect drug stability and delivery.

The patch is applied to a clean, dry, hair‑free area of the upper torso or upper arm. Press the patch firmly for at least 30 seconds to ensure good skin contact, then cover with a protective dressing if needed. The patch remains in place for the prescribed duration (typically 7 days) before being replaced with a new one.

The most serious risks include respiratory depression, especially in opioid‑naïve patients or when combined with other depressants, severe hypotension, and rare cardiac arrhythmias such as QT prolongation. Patients should be monitored for signs of shallow breathing, excessive sedation, dizziness, or fainting, and medical attention sought immediately if these occur.

Norspan is contraindicated in individuals with known hypersensitivity to buprenorphine or any component of the patch, in patients with severe respiratory insufficiency, acute severe asthma, or in those receiving other opioid analgesics for acute pain. It should also be avoided in patients with uncontrolled severe hepatic impairment unless specifically directed by a specialist.